- Strategic portfolio expansion—Evonik offers phthalate-free and bio-based plasticizers
- New ELATUR® product brand
- New production plant at Marl Chemical Park
Evonik is launching a new generation of PVC plasticizers under the ELATUR® product brand. With this strategic portfolio expansion, Evonik is consistently developing its range of sustainable plasticizers.
In June 2013 production started for the phthalate-free plasticizer 1,2-Cyclohexa dicarboxylic acid diisononyl ester. Evonik’s new production plant came on stream at Marl Chemical Park with an annual production capacity of 40,000 metric tons. Investment was in the double-digit million euro range. The phthalate-free plasticizer is sold under the ELATUR®CH brand name.
Consistent research will help to add further innovative products to the new generation of plasticizers. This includes marketing bio-based plasticizers that Evonik plans to launch additionally under the ELATUR® brand name. Negotiations with cooperation partners are at the final stage.
To develop the plasticizers further, Evonik operates its own research and development laboratory at Marl Chemical Park, offering also technical customer service.
"The expansion of the portfolio with phthalate-free and bio-based plasticizers is an ideal addition to our existing VESTINOL® product family that has been tried and tested for decades," explains Dr. Rainer Fretzen, Head of Evonik’s Performance Intermediates Business Line. "With our new plasticizers from the ELATUR® brand, our customers now have an even wider portfolio from which to choose the plasticizer that best suits their individual requirements. We thus offer our customers a complete service including logistics and technical support from a single source."
Plasticizers from Evonik are primarily used in the plastics, automotive, and construction industry.
Evonik, the creative industrial group from Germany, is one of the world leaders
in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.
Evonik is active in over 100 countries around the world. In fiscal 2012 more than 33,000 employees generated sales of around €13.6 billion and an operating profit (adjusted EBITDA) of about €2.6 billion.
In so far as forecasts or expectations are expressed in this Investor Relations News or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.